Net Income (Loss) Attributable to Parent in USD of Talis Biomedical Corp from Q1 2020 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Talis Biomedical Corp quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2020 to Q2 2024.
  • Talis Biomedical Corp Net Income (Loss) Attributable to Parent for the quarter ending 30 Jun 2024 was -$8.85M, a 41.1% increase year-over-year.
  • Talis Biomedical Corp Net Income (Loss) Attributable to Parent for the twelve months ending 30 Jun 2024 was -$51M, a 40.5% increase year-over-year.
  • Talis Biomedical Corp annual Net Income (Loss) Attributable to Parent for 2023 was -$62M, a 45.1% increase from 2022.
  • Talis Biomedical Corp annual Net Income (Loss) Attributable to Parent for 2022 was -$113M, a 41.2% increase from 2021.
  • Talis Biomedical Corp annual Net Income (Loss) Attributable to Parent for 2021 was -$192M, a 111% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Talis Biomedical Corp Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$51M -$8.85M +$6.19M +41.1% 01 Apr 2024 30 Jun 2024 10-Q 19 Aug 2024
Q1 2024 -$57.2M -$13M +$4.8M +26.9% 01 Jan 2024 31 Mar 2024 10-Q 19 Aug 2024
Q4 2023 -$62M -$13.5M +$13.5M +50% 01 Oct 2023 31 Dec 2023 10-K 28 Mar 2024
Q3 2023 -$75.5M -$15.7M +$10.3M +39.7% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2023
Q2 2023 -$85.8M -$15M +$12M +44.3% 01 Apr 2023 30 Jun 2023 10-Q 19 Aug 2024
Q1 2023 -$97.8M -$17.8M +$15.2M +46.1% 01 Jan 2023 31 Mar 2023 10-Q 19 Aug 2024
Q4 2022 -$113M -$26.9M +$1.73M +6.02% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024
Q3 2022 -$115M -$26M +$12.4M +32.3% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$127M -$27M +$37.5M +58.1% 01 Apr 2022 30 Jun 2022 10-Q 14 Nov 2023
Q1 2022 -$165M -$33.1M +$27.4M +45.4% 01 Jan 2022 31 Mar 2022 10-Q 14 Nov 2023
Q4 2021 -$192M -$28.7M +$15.5M +35.2% 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023
Q3 2021 -$208M -$38.4M -$8.9M -30.2% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022
Q2 2021 -$199M -$64.5M -$54.4M -542% 01 Apr 2021 30 Jun 2021 10-Q 03 Nov 2022
Q1 2021 -$144M -$60.5M -$53.1M -720% 01 Jan 2021 31 Mar 2021 10-Q 03 Nov 2022
Q4 2020 -$91.1M -$44.2M 01 Oct 2020 31 Dec 2020 10-K 15 Mar 2022
Q3 2020 -$29.5M 01 Jul 2020 30 Sep 2020 10-Q 16 Nov 2021
Q2 2020 -$10M 01 Apr 2020 30 Jun 2020 10-Q 16 Nov 2021
Q1 2020 -$7.37M 01 Jan 2020 31 Mar 2020 10-Q 16 Nov 2021

Talis Biomedical Corp Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$62M +$51M +45.1% 01 Jan 2023 31 Dec 2023 10-K 28 Mar 2024
2022 -$113M +$79M +41.2% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024
2021 -$192M -$101M -111% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023
2020 -$91.1M 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.